ARTICLE | Emerging Company Profile
Pretzel: modulating the mitochondrial genome
Arch-incubated newco launched Monday with $72.5M and three platforms to tackle mitochondrial diseases
September 14, 2022 11:21 PM UTC
Pretzel launched Monday with three platforms to restore mitochondrial function in a variety of indications, including both primary and secondary mitochondrial diseases, using DNA editing and small molecules.
The company debuted with a $72.5 million series A financing led by Arch Venture Partners and Mubadala Capital. HealthCap, Cambridge Innovation Capital, Cambridge Enterprise, Angelini Ventures, GV, Invus, Eir Ventures, GU Ventures and Karolinska Institute Holding also participated...